The Year in Acute Coronary Syndrome  by Giugliano, Robert P. & Braunwald, Eugene
Journal of the American College of Cardiology Vol. 63, No. 3, 2014
 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.10.041YEAR IN CARDIOLOGY SERIES
The Year in Acute Coronary Syndrome
Robert P. Giugliano, MD, SM, Eugene Braunwald, MD
Boston, MassachusettsIn this year’s report on acute coronary syndromes (ACS),
we have expanded the scope to include ST-segment eleva-
tion myocardial infarction (STEMI) in addition to non–
ST-segment elevation ACS. In this report, we review
selected highlights across the spectrum of ACS published
between June 2012 and September 2013.Background
It is estimated that there were over 1.1 million patients with
diagnoses of ACS discharged from U.S. hospitals in 2010,
of whom 74% were classiﬁed as having myocardial infarction
(MI) (1). Despite improvements in the management of
coronary heart disease risk factors, the annual rates of acute
myocardial infarction (AMI) have been fairly stable in the
United States over the past decade. The impact of enhanced
prevention has been offset by the use of more sensitive
biomarkers of cardiac necrosis, speciﬁcally cardiac troponin
(cTn), to deﬁne MI (2), as well as the increase in comor-
bidities that increase the risk for developing ACS, including
diabetes, metabolic syndrome, and chronic kidney disease, as
well as the overall aging of the population. The percent of
patients with ACS classiﬁed as having STEMI ranges from
29% to 47% in recent databases and registries, depending on
the methods used to identify patients and the population
being studied (1). This percent is decreasing relative to non-
STEMI (NSTEMI), in part because of temporal changes in
the risk factor proﬁle (reductions in “classic” risk factors such
as smoking and hypertension but increases in the afore-
mentioned comorbidities) (3). With the broader acceptance
of the third universal deﬁnition of MI (4) (Table 1), we
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accepted October 21, 2013.Indeed, as the sensitivity of cTn measurements has
increased, the fraction of patients with unstable angina (UA)
(i.e., those with non–ST-segment elevation ACS and no
evidence of myocardial necrosis) is steadily declining (2).
With the introduction of so-called high-sensitivity cTn
(hs-cTn) into clinical practice in a number of countries
(other than the United States), almost all patients with
ischemic discomfort at rest consistent with ACS have
elevations of hs-cTn and are being reclassiﬁed as having
NSTEMI (5). Patients with chest pain at rest without
elevation of hs-cTn on 2 measurements made 2 to 4 h
apart most likely have nonischemic chest pain.New Guidelines
New guidelines for the management of STEMI were
released by the American College of Cardiology Foundation
(ACCF) and American Heart Association (AHA) (6) and
the European Society of Cardiology (7) during the past year.
In addition, the ACCF and AHA published an update of
the guideline for UA and NSTEMI guideline (8). Key
changes in these guidelines are summarized in Table 2.
Two important updates to the STEMI guideline (6)
include a new target of no more than 120 min from ﬁrst
medical contact to initiation of ﬁbrinolysis (for those not
undergoing primary percutaneous coronary intervention
[PCI]) and the early initiation of therapeutic hypothermia in
survivors of cardiac arrest, followed by immediate PCI
when appropriate. Across the ACS spectrum, these updated
guidelines (6–8) now recommend the use of the more potent
oral antiplatelet drugs (prasugrel or ticagrelor) as alternatives
to clopidogrel and provide speciﬁc advice on how to mini-
mize bleeding, particularly among patients who require
dual-antiplatelet therapy (DAPT) in addition to oral
anticoagulation.Pathophysiology
Three important reports extended the framework for
understanding the basic mechanisms leading to ACS:
1) Libby (9) described an updated model in terms of cellular
and molecular pathways that underlie the pathogenesis of
ACS, with a central role for inﬂammation, which drives
plaque disruption and thrombosis (Fig. 1). This more
nuanced understanding of the pathophysiology of ACS has
broadened our approach beyond management of a focal
Table 1 Third Universal Deﬁnition of Myocardial Infarction
Deﬁnition of myocardial infarction
Criteria for acute myocardial infarction
The term acute myocardial infarction (MI) should be used when there is evidence of
myocardial necrosis in a clinical setting consistent with acute myocardial
ischemia. Under these conditions any one of the following criteria meets the
diagnosis for MI:
 Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac
troponin (cTn)] with at least one value above the 99th percentile upper refer-
ence limit (URL) and with at least one of the following:
- Symptoms of ischemia.
- New or presumed new signiﬁcant ST-segment–T wave (ST–T) changes or
new left bundle branch block (LBBB).
- Development of pathological Q waves in the ECG.
- Imaging evidence of new loss of viable myocardium or new regional wall
motion abnormality.
- Identiﬁcation of an intracoronary thrombus by angiography or autopsy.
 Cardiac death with symptoms suggestive of myocardial ischemia and
presumed new ischemic ECG changes or new LBBB, but death occurred before
cardiac biomarkers were obtained, or before cardiac biomarker values would be
increased.
 Percutaneous coronary intervention (PCI) related MI is arbitrarily deﬁned by
elevation of cTn values (>5 x 99th percentile URL) in patients with normal
baseline values (99th percentile URL) or a rise of cTn values >20% if the
baseline values are elevated and are stable or falling. In addition, either (i)
symptoms suggestive of myocardial ischemia or (ii) new ischemic ECG changes
or (iii) angiographic ﬁndings consistent with a procedural complication or (iv)
imaging demonstration of new loss of viable myocardium or new regional wall
motion abnormality are required.
 Stent thrombosis associated with MI when detected by coronary angiography or
autopsy in the setting of myocardial ischemia and with a rise and/or fall of
cardiac biomarker values with at least one value above the 99th percentile URL.
 Coronary artery bypass grafting (CABG) related MI is arbitrarily deﬁned by
elevation of cardiac biomarker values (>10 x 99th percentile URL) in patients
with normal baseline cTn values (99th percentile URL). In addition, either (i)
new pathological Q waves or new LBBB, or (ii) angiographic documented new
graft or new native coronary artery occlusion, or (iii) imaging evidence of new
loss of viable myocardium or new regional wall motion abnormality.
Criteria for prior myocardial infarction
Any one of the following criteria meets the diagnosis for prior MI:
 Pathological Q waves with or without symptoms in the absence of non-ischemic
causes.
 Imaging evidence of a region of loss of viable myocardium that is thinned and
fails to contract, in the absence of a non-ischemic cause.
 Pathological ﬁndings of a prior MI.
Reprinted with permission from Thygesen et al. (4).
ECG ¼ electrocardiogram.
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202intracoronary stenosis. 2) Crea and Liuzzo (10) classiﬁed
ACS into 3 groups (Fig. 2): obstructive atherosclerosis
with systemic inﬂammation, obstructive atherosclerosis with-
out systemic inﬂammation, and ACS without obstructive
atherosclerosis (e.g., Prinzmetal’s angina, amphetamine-
induced coronary spasm). 3) Falk and a group of cardiac
pathologists (11) described 3 common coronary artery pla-
que morphologies resulting in thrombosis (plaque rupture,
plaque erosion, and disruptive nodular calciﬁcations pro-
truding into the coronary artery lumen, known as “calciﬁed
nodules”). These latter investigators described several con-
tributors to the “vulnerable plaque,” including structural
determinants of the plaque (size of the necrotic core,
thickness and degree of inﬂammation within the ﬁbrous
cap), plaque neorevascularization and inﬁltration with
hemoglobin-stimulated macrophages (both of which increase
the risk for intraplaque hemorrhage), and the pattern ofcalciﬁcation (spotty calciﬁcation confers higher risk com-
pared with dense localized calciﬁcation). It is hoped that
continued work on the pathogenesis of ACS will lead to new
diagnostic algorithms and therapeutic targets.
The search continues for interventions, other than prompt
revascularization, to reduce infarct size in patients with
STEMIs. An intriguing study in swine in which the left
anterior coronary artery was occluded showed that unloading
the left ventricle with left atrial–femoral artery bypass when
added to coronary occlusion resulted in further reduction of
myocardial infarct size (12). Although this approach cannot
be applied routinely in the catheterization laboratory in all
patients with STEMI, it could be lifesaving in those with
large infarctions.
Risk Factors
Several reports published during the past year explored
genetic risk factors for ACS. Micro-ribonucleic acids
(miRNAs) are noncoding ribonucleic acid molecules, 21 to
23 nucleotides long, that regulate the expression of target
genes. After multivariate adjustment, 3 circulating miRNAs
(126, 233, and 197) were found to be risk factors for the
development of future MI (13). Other miRNAs have been
found to be associated with reduced myocardial salvage,
more pronounced reperfusion injury, and left ventricular
remodeling after ﬁrst STEMI (14,15). The discovery of
miRNAs represents a major advance in biology that is likely
to aid in the elucidation of the pathobiology of many
conditions (including ACS), may provide families of new
biomarkers, and might open the possibility for the devel-
opment of new therapies. For example, miRNAs can be
“silenced” by speciﬁc antagonists, known as antagomirs,
that might be designed to modify target proteins that pre-
dispose plaques to rupture.
New data on hormonal contraceptives and nonsteroidal
anti-inﬂammatory drugs provided new insights regarding
the increased risk for ACS with these classes of medications.
In an analysis of over 1.6 million women the use of ethinyl
estradiol was associated with increases in the risk for
MI (16). A nationwide Danish cohort study of almost
100,000 patients alive at 30 days after ﬁrst MI found that
nonsteroidal anti-inﬂammatory drugs (prescribed to 44% of
the cohort) within 5 years after the index MI increased the
risk for coronary death or nonfatal MI by 30% after 1 year
and 41% after 5 years (17). These ﬁndings provide addi-
tional support for the Class III recommendations (i.e.,
contraindications) for estrogen-containing hormones (6)
and nonsteroidal anti-inﬂammatory drugs (6–8) present in
current ACS guidelines.
Two reports call attention to speciﬁc groups of patients
who are at high risk for initial and/or recurrent ACS events.
1) Mild psoriasis was associated with a 30% increase in the
adjusted risk for MI, while severe psoriasis was indepen-
dently associated with increased risk for MI and cardiovas-
cular (CV) mortality of 70% and 40%, respectively (18).
Table 2 Key Changes to the ACS Practice Guidelines
STEMI (6,7) 1. Use 120 min from ﬁrst medical contact as the benchmark for ﬁbrinolytic therapy (ACCF/AHA and ESC: Class I, LOE A).
2. Transfer of patients to a PCI-capable hospital for coronary angiography between 3 and 24 h after successful ﬁbrinolysis
(ACCF/AHA: Class IIa, LOE B; ESC: Class IIa, LOE A).
3. Therapeutic hypothermia should be started as soon as possible in comatose patients with STEMI and out-of-hospital cardiac arrest due to
ventricular ﬁbrillation or pulseless ventricular tachycardia (ACCF/AHA and ESC: Class I, LOE B). Immediate angiography with PCI if
appropriate should follow resuscitation (ACCF/AHA and ESC: Class I, LOE B).
4. Use of intra-aortic counterpulsation in patients with cardiogenic shock downgraded from a Class I to Class II recommendation (ACCF/AHA:
Class IIa, LOE B; ESC: Class IIb, LOE B).
5. In patients undergoing PCI, prasugrel or ticagrelor as the second oral antiplatelet agent in addition to aspirin is recommended as an
alternative to clopidogrel (ACCF/AHA: Class I, LOE B), while the ESC prefers the newer agents over clopidogrel (ESC: Class I, LOE A).
6. To limit the risk for bleeding in patients with indications for triple antithrombotic therapy with VKA, aspirin, and a P2Y12 inhibitor, the
duration of triple therapy should be minimized to the extent possible (ACCF/AHA and ESC: Class I, LOE C), and a target INR of 2.0–2.5
might be considered (ACCF/AHA: Class IIb, LOE C).
UA/NSTEMI (ACCF/AHA) (8) 1. Options for the second oral antiplatelet agent include ticagrelor (at admission or at the time of PCI) and prasugrel (at the time of PCI) as
alternatives to clopidogrel (Class I, LOE B).
2. A 600-mg loading dose of clopidogrel is recommended as early as possible before or at the time of PCI (Class I, LOE B).
3. DAPT should be continued for up to 12 months (Class I, LOE B). Continuation of a P2Y12 inhibitor beyond 12 months may be considered in
patients with DES (Class IIb, LOE C).
4. The recommended dose of aspirin is 81 mg in combination with ticagrelor (Class I, LOE B) and after PCI (Class IIa, LOE B).
5. Targeting a lower INR (2.0–2.5) might be reasonable in patients who require VKA in addition to aspirin þ P2Y12 inhibitor (Class IIb, LOE C).
ACCF ¼ American College of Cardiology Foundation; ACS ¼ acute coronary syndrome(s); AHA ¼ American Heart Association; DAPT ¼ dual-antiplatelet therapy; DES ¼ drug-eluting stent(s); ESC ¼ European
Society of Cardiology; INR ¼ international normalized ratio; LOE ¼ level of evidence; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-
segment elevation myocardial infarction; UA ¼ unstable angina; VKA ¼ vitamin K antagonist.
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therapies used to manage psoriasis have either shown no
beneﬁt or the potential for harm early after MI, identiﬁca-
tion of the optimal treatment plan for these patients remains
an unmet need. 2) In patients with non–ST-segment ele-
vation ACS who experienced ventricular tachycardia (VT)
or ventricular ﬁbrillation (VF), either early (within 48 h) or
late (>48 h) after admission, the adjusted hazard ratios
(HRs) for mortality at 1 year were 7.4 and 15, respectively,
compared with no VT or VF during the index hospital stay
(19). These ﬁndings are important for 2 reasons. They
demonstrate that ventricular arrhythmias early after MI may
not uniformly represent benign reperfusion arrhythmias, as
previously had been thought. Also, the very high risk for
VT or VF occurring >48 h after admission raises concern
regarding the safety of early discharge for patients who had
experienced even brief bouts of VT and the need for risk
stratiﬁcation and better therapies to prevent and treat late
ventricular arrhythmias.
We end this section with a brief discussion of a novel
dynamic risk score in patients with STEMI (20). Most
risk scores for ACS, such as the TIMI (for a list of trial
acronyms, see Table 3) risk score for STEMI (21), are based
on ﬁndings at the time of the patient’s initial presentation.
However, they do not take into account events that occur
during the hospital stay. The dynamic TIMI risk score for
STEMI (20) includes 6 clinical events occurring after
admission (reinfarction, stroke, major bleed, congestive
heart failure or shock, arrhythmia [VT, VF, or atrial ﬁbril-
lation], and renal failure) that affect the risk for mortality
adversely (Table 4). Addition of these clinical events resulted
in a high discriminatory capacity (C-statistics of 0.76 in
the derivation set and 0.81 in the validation set) and
improved net reclassiﬁcation (0.33 in the derivation set,
0.35 in the validation set) over the original TIMI risk scorefor STEMI (21) for the prediction of 1-year mortality.
This dynamic score could help clinicians tailor discharge
medical regimens and guide decisions regarding discharge
location, cardiopulmonary rehabilitation, and timing of
follow-up visits.
Biomarkers
The ACCF released an expert consensus document (22) that
focuses on the practical issues related to elevated cTn levels
in clinical practice. A conceptual model proposed 3 cate-
gorizes of cTn elevation: 1) ischemic myocardial damage
(i.e., MI), 2) nonischemic causes of myocardial damage (e.g.,
myocarditis), and 3) analytical issues that may be either assay
based (e.g., calibration errors) or sample based. In Figure 3,
we highlight the importance of nonischemic causes of cTn
elevation, including both cardiac diagnoses (e.g., congestive
heart failure) and systemic illnesses (e.g., sepsis), because
these are frequently encountered in hospital care and account
for a large number of unnecessary requests for cardiology
consultations. It is essential that healthcare providers
incorporate the clinical context of an elevated cTn level to
help guide the triage, diagnostic work-up, and treatment
plans for these patients, and not reﬂexively label all cTn
elevations as indicating MI. In addition, a prospective
analysis of 887 unselected patients with acute chest pain
found that a simple algorithm that incorporates ST-segment
elevation, the level of hs-cTn (currently not available in the
United States) at presentation, and the absolute change in
hs-cTn during the ﬁrst hour performed well (C-statistic ¼
0.94) in separating AMI from noncoronary diagnoses (23).
As increasingly sensitive cTn assays become available, we
anticipate that most patients will have detectable levels of
cTn after PCI, but the clinical signiﬁcance of minor releases
of cTn in this setting is unclear. One analysis concluded
Figure 1 Inﬂammatory Pathways Pre-Disposing Coronary Arteries to Rupture and Thrombosis
A cross-section of an atheromatous plaque at the bottom of the ﬁgure shows the central lipid core containing macrophage foam cells (yellow) and T cells (blue). Arterial smooth
muscle cells (red) present in the intima and media are the source of arterial collagen (triple helical structures). Activated T cells secrete cytokine interferon-gamma, which
inhibits the production of the new, interstitial collagen required to repair and maintain the plaque’s protective ﬁbrous cap (top left). T cells may also activate macrophages in the
intima by expressing CD40 ligand, which engages the CD40 receptor on the phagocyte. This inﬂammatory signaling causes overproduction of matrix metalloproteinases (MMPs)
1, 8, and 13, which catalyze the initial rate-limiting step in collaged breakdown (top right). CD40 ligation also causes macrophages to overproduce tissue-factor procoagulant.
These multiple consequences of inﬂammatory signaling each contribute to the instability of the plaque’s ﬁbrous cap. Reprinted with permission from Libby (9).
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the upper limit of normal after PCI correlated with cTn
elevations of 50-fold to 100-fold in both frequency and risk
for mortality 1 year after PCI (24).
Among 2,544 patients presenting with symptoms
consistent with ACS, the combination of normal hs-cTn at
presentation and 2 h later, no ischemic changes on elec-
trocardiography, and a TIMI risk score for UA or NSTEMI
(25) of 0 or 1 identiﬁed approximately 40% of patients
in whom the rate of major adverse cardiac events through
30 days was <1% and who therefore were good candidates
for early discharge (26). It is likely that many of these
patients may not actually have had ACS (5). Another study
in 1,967 patients presenting to emergency departments with
chest pain onset within 6 h demonstrated that the combi-
nation of negative cTn (not high sensitivity), copeptinlevel <14 pmol/l, and nondiagnostic electrocardiographic
ﬁndings could rule out AMI in the majority of patients
without serial blood draws (27). These studies highlight how
the incorporation of cTn into a rapid assessment at
presentation could help improve efﬁciency in the diagnosis
and risk stratiﬁcation of patients with chest pain.
From the many reports describing novel biomarkers asso-
ciated with clinical outcomes in ACS published during the
past year, we have selected 4 markers for this year’s review.
1) pregnancy-associated plasma protein–A, a zinc-binding
metalloproteinase found in vulnerable plaques that cleaves
insulin-like growth factor–4 from insulin-like growth factor–1
and that causes destabilization of the ﬁbrous plaque, was
measured at baseline in 3,782 patients with non–ST-segment
elevation ACS in the MERLIN–TIMI 36 trial (28). After
multivariate adjustment for baseline cTn I and other risk
Figure 2 A New Pathogenetic Classiﬁcation of ACS
Simple clinical descriptors provide a framework for understanding the basic mechanisms responsible for coronary instability in homogenous groups of patients with acute
coronary syndromes (ACS) that might help in the search for new diagnostic algorithms and therapeutic targets: 1) patients with obstructive atherosclerosis (ATS) and systemic
inﬂammation; 2) patients with obstructive atherosclerosis without systemic inﬂammation; and 3) patients without obstructive atherosclerosis. Reprinted with permission from
Crea and Liuzzo (10).
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protein–A was found to be independently associated with
increased risk for CV death or MI at 30 days (HR: 1.62;
p ¼ 0.006) and 1 year (HR: 1.35; p ¼ 0.012). 2) Ischemia-
mediated changes to myocardial cell surface molecule
expression render the cell membrane a target for the
complement system, leading to the formation of a membrane
attack complex (MAC), which leads to cell lysis. In an analysisTable 3 Trial Acronyms
Acronym
ARCTIC Assessment by a Double Randomization of a Conventio
Implantation and of Treatment Interruption Versus C
ATLAS ACS 2 Second Trial of Anti-Xa Therapy to Lower Cardiovascula
CHAMPION PHOENIX Cangrelor Versus Standard Therapy to Achieve Optimal
COMFORTABLE AMI Comparison of Biolimus Eluted From an Erodible Stent
DAPT Dual Antiplatelet Therapy
EMBRACE-STEMI Evaluation of the Myocardial Effects of Bendavia for Re
EXAMINATION Clinical Evaluation of the Xience-V Stent in Acute Myoc
GUSTO Global Utilization of Streptokinase and Tissue Plasmino
HORIZONS-AMI Harmonizing Outcomes With Revascularization and Ste
IABP-SHOCK II Intraaortic Balloon Pump in Cardiogenic Shock II
MERLIN Metabolic Efﬁciency With Ranolazine for Less Ischemia
PARADOX The Inﬂuence of Smoking Status on Prasugrel and Clop
PLATO Platelet Inhibition and Patient Outcomes
RIFLE-STEACS Radial Versus Femoral Randomized Investigation in ST
RIVAL A Trial of Trans-Radial Versus Trans-Femoral Percutane
Myocardial Infarction Managed With an Invasive Stra
TIMI Thrombolysis in Myocardial Infarction
TRILOGY Targeted Platelet Inhibition to Clarify the Optimal Strat
TRITON Trial to Assess Improvement in Therapeutic Outcomes
TRIUMPH Translational Research Investigating Underlying Dispari
TWENTE The Real-World Endeavor Resolute Versus Xience V Dru
WOEST What Is the Optimal Antiplatelet and Anticoagulant The
XAMI Xience V Stent vs. Cypher Stent in Primary PCI for Acutof 725 patients with STEMI treated with primary PCI,
elevated concentrations of soluble MAC (a stable nonlytic
form of MAC that can be used to estimate MAC) after
multivariate adjustment were associated with all-cause
mortality (HR: 1.81; p ¼ 0.029) and major adverse CV
events (HR: 1.70; p ¼ 0.006) (29). 3) Interleukin-17 is
produced by a recently described lineage of CD4þ T cells,
plays a role in host immunity and the pathophysiology ofDeﬁnition
nal Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent
ontinuation One Year After Stenting
r Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome
Management of Platelet Inhibition
Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction
ducing Reperfusion Injury in Patients With Acute Coronary Events–STEMI
ardial Infarction
gen Activator for Occluded Coronary Arteries
nts in Acute Myocardial Infarction
in Non–ST-Elevation Acute Coronary Syndromes
idogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
-Elevation Acute Coronary Syndrome
ous Coronary Intervention Access Site Approach in Patients With Unstable Angina or
tegy
egy to Medically Manage Acute Coronary Syndromes
by Optimizing Platelet Inhibition With Prasugrel
ties in Acute Myocardial Infarction Patients’ Health Status
g-Eluting Stent Study in Twente
rapy in Patients With Oral Anticoagulation and Coronary Stenting
e Myocardial Infarction
Table 4 Dynamic TIMI Risk Score for STEMI
Points
Baseline TIMI risk score for STEMI 0 to 14 possible points
Age, yrs
65 to 74 2
75 3
Diabetes, hypertension, or angina 1
Systolic blood pressure <100 mm Hg 3
Heart rate >100/min 2
Killip class II, III, or IV 2
Weight <67 kg 1
Anterior ST-segment elevation or left bundle
branch block
1
Time to treatment >4 h 1
Added index hospitalization events for dynamic score 0 to 15 possible points
Recurrent myocardial infarction 1
Stroke 5
Major bleeding 1
Congestive heart failure or shock 3
Arrhythmia 2
Renal failure 3
Dynamic TIMI risk score 0 to 29 possible points
The 6 clinical events after hospital admission (bottom half) are added to the baseline risk factors
(top half) of the original TIMI risk score for STEMI to yield the dynamic TIMI risk score, which ranges
from 0 to 29 points. Reprinted with permission from Amin et al. (20).
STEMI ¼ ST-segment elevation myocardial infarction.
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opment of an unstable plaque. In an analysis of 981 patients
enrolled in a French registry of patients withMI, low levels of
interleukin-17 were independently associated with increased
risk for death or reinfarction at 2 years (HR: 1.40; p ¼ 0.03)
after adjustment for CV risk factors (30). 4) Koga et al. (31)
reported that higher levels of circulating pentraxin 3, a novelFigure 3 Non-MI Causes of Troponin Elevation
Causes of elevated troponin reﬂecting direct myocardial damage, other than
myocardial infarction (MI), can be classiﬁed into 2 broad groups: 1) cardiac
etiologies and 2) systemic processes. Reprinted with permission from Newby et al.
(22).inﬂammatory marker, were associated with thin-cap vulner-
able plaques, as determined by optical coherence tomography.
Imaging
There is an increasing effort to identify noninvasive imaging
modalities to predict acute clinical CV events in patients
suspected of having coronary artery disease. Coronary mag-
netic resonance angiography was found to be helpful in
the risk stratiﬁcation of patients with suspected CAD who
were followed for 25 months (32). Patients with signiﬁcant
luminal narrowing (50% diameter reduction) were at higher
risk for cardiac death, MI, UA, or need for revascularization
(6.3% vs. 0.3%, p ¼ 0.001) compared with those without
signiﬁcant stenoses.
Building on the prior data supporting a role for computed
tomographic angiography (CTA) to assist in the rapid triage
of patients presenting with acute chest pain to hospital
emergency departments described in last year’s review (33),
Ferencik et al. (34) demonstrated that a CTA-based score
incorporating morphologic characteristics of coronary lesions
(stenosis length, plaque volume and attenuation, remodeling
index, presence of spotty calcium) was quite accurate
(C-statistic ¼ 0.83) in the detection of ACS in a cohort of
patients with acute chest pain and signiﬁcant stenosis by
CTA. A systematic review and meta-analysis of 4 ran-
domized trials of 1,869 patients undergoing CTA and 1,397
managed with usual care showed that CTA reduced the
mean cost in the emergency department and shortened
lengths of hospital stay (35). Furthermore, in an analysis by
Poon et al. (36), routine CTA of patients presenting with
chest pain to an emergency department reduced health
expenditures largely because the use of this technique
reduced the incidence of patients’ return to the emergency
department within 30 days.
Two catheter-based imaging techniques are being evalu-
ated for the characterization of coronary plaques in patients
with ACS. Using optical coherence tomography, plaque
rupture was found to be responsible for the culprit lesion in
44% of 126 patients, while 31% had plaque erosion; the
latter was more frequently observed in younger patients
with NSTEMI, whose plaques had thicker ﬁbrous caps and
less lipid than those with plaque rupture (37). An interesting
alternative approach is the use of a catheter designed to
provide near-infrared spectroscopy, which allows the detec-
tion of lipid in the plaques. Madder et al. (38) reported that
use of this catheter in patients with acute STEMI revealed that
the lipid core in culprit plaques was larger than those observed
in nonculprit arteries, thereby providing a “biochemical
signature” of the culprit plaque.
Antiplatelet Therapy
Antiplatelet therapy is one of the cornerstones of the
management of ACS. From a large body of research, we
have selected 5 areas to highlight in this year’s review.
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drugs. Cangrelor, an intravenous, rapidly acting, potent,
yet reversible P2Y12 inhibitor, was compared with clopi-
dogrel in the double-blind, double-dummy CHAMPION
PHOENIX trial of 11,145 patients (44% of whom had
ACS) undergoing either urgent or elective PCI (39). Can-
grelor signiﬁcantly reduced the odds of both the primary
CV composite endpoint of death, MI, ischemia-driven
revascularization, or stent thrombosis at 48 h after ran-
domization by 20% among the 2,810 patients with
non–ST-segment elevation ACS and by 25% among the
1,991 patients with STEMI, rates that were statistically
similar to the signiﬁcant 22% reduction observed in the
overall trial population (Fig. 4). In addition, cangrelor
reduced the odds of stent thrombosis (by 38%) through
48 h without increasing bleeding in the overall population,
without heterogeneity across the population stratiﬁed by
type of ACS at presentation. This trial demonstrated the
beneﬁt of intense but short-duration inhibition of P2Y12
to reduce periprocedural complications, particularly MI
and stent thrombosis. In contrast, the potent oral thie-
nopyridine prasugrel did not reduce the composite of CV
death, MI, or stroke among medically managed patients
with non–ST-segment elevation ACS compared with
clopidogrel, in the TRILOGY ACS trial (40). These
2 trials (CHAMPION PHOENIX and TRILOGY
ACS), considered in the light of prior studies of potent
P2Y12 inhibitors in patients with ACS, suggest that moreFigure 4 Primary Efﬁcacy and Safety Results From the CHAMPION P
The primary efﬁcacy composite included death, myocardial infarction, ischemia-driven rev
safety endpoint was moderate or severe bleeding according to the GUSTO scale. ACS ¼
STEMI ¼ ST-segment elevation myocardial infarction. Modiﬁed with permission from Bhaintensive blockade appears most beneﬁcial in high-risk
patients during PCI (as had been observed with prasugrel
in the TRITON–TIMI 38 trial [41]), whereas the beneﬁt of
such therapy over the long term in those patients who are
managed medically deserves further prospective evaluation.
A randomized trial of bedside monitoring to adjust
antiplatelet therapy. In the ARCTIC trial (42), 2,440
patients scheduled for coronary stent implantation (30%
with prior MI, 27% with non–ST-segment elevation ACS)
were randomized to a strategy of platelet-function moni-
toring using the VerifyNow assay (Accumetrics, San Diego,
California), followed by intensiﬁcation of the antiplatelet
regimen in patients with high platelet reactivity, compared
with a conventional strategy with no monitoring or adjust-
ment of the antiplatelet regimen. Despite increasing the
antiplatelet therapy in over one-third of the patients in the
platelet monitoring group, there were no differences in the
primary CV composite endpoint (death, MI, stent throm-
bosis, stroke, or urgent revascularization), the major
secondary endpoint of stent thrombosis or any urgent
revascularization, or major bleeding. Several potential
explanations for the lack of improvement in clinical
outcomes in ARCTIC and 3 prior similar studies have been
offered, including a suboptimal cut point for high platelet
reactivity, a need for even more potent antiplatelet agents in
patients with high reactivity, and the observation that some
clinical ischemic events (e.g., procedural complications)
cannot be inﬂuenced by antiplatelet therapy. Until moreHOENIX Trial by Diagnosis at Presentation
ascularization, or stent thrombosis through 48 h after randomization. The primary
acute coronary syndromes; HR ¼ hazard ratio; STE ¼ ST-segment elevation;
tt et al. (39).
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recommendations in the current ACS guidelines that do not
endorse routine testing of platelet function (6–8).
Studies exploring shorter duration of DAPT. DAPT is
recommended for at least 12 months after ACS, whether it
is secondary to STEMI (6) or non–ST-segment elevation
ACS (8) and whether patients receive intracoronary stents or
not. During the past year, new ﬁndings regarding the risks
and beneﬁts of prolonged DAPT after the placement of
a drug-eluting stent (DES) were reported. In a meta-analysis
including 8,231 patients (61% with ACS) undergoing PCI
with DES from 4 randomized trials, extended use of DAPT
(>12 months) signiﬁcantly increased the risk for TIMI
major bleeding by 2.6-fold but did not reduce mortality, MI,
or stroke compared with control (3 to 12 months of DAPT)
(43). Further support for stopping DAPT >12 months after
DES placement come from the TWENTE trial (44), which
showed a very low rate of late stent thrombosis (0.3%)
between 12 and 24 months among patients who received
second-generation DES (either zotarolimus or everolimus),
95% of whom stopped clopidogrel at 12 months. However,
interruption of DAPT within the ﬁrst 90 days after DES
placement is not advised.
Certain high-risk subgroups (e.g., patients undergoing
intracoronary stent placement into a saphenous vein graft
[45]) are at increased risk (adjusted incidence ratio: 1.33) for
stent thrombosis within the ﬁrst 3 months, regardless of stent
type, if clopidogrel is stopped before day 90 after stent
placement. Although interruptions in DAPT were common
within the ﬁrst year of a registry enrolling 1,622 patients
(59% of whom had ACS) at 29 Spanish hospitals, they
were typically brief (median 7 days) and not associated with
a statistically signiﬁcant increase in the risk for stent throm-
bosis (46). The DAPT Study (NCT00977938) enrolled
more than 26,000 patients who had received intracoronary
stents (either bare-metal stents [BMS] or DES) and were
treated with DAPT. After 12 months, patients who were free
of major CV events and bleeding were randomized to either
placebo (12-month DAPT arm) or an additional 18 months
of thienopyridine (30-month DAPT arm). This trial repre-
sents the ﬁrst adequately powered evaluation of the clinical
efﬁcacy and safety of differing durations of DAPT; results are
anticipated in 2014.
Reduction of stent thrombosis with ticagrelor.
Analysis of the TRITON–TIMI 38 trial in patients with
ACS undergoing coronary stent implantation showed that,
compared with clopidogrel, the administration of prasugrel
reduced stent thrombosis by 50% (41). In the PLATO trial,
which compared ticagrelor with clopidogrel, 11,289 patients
with ACS received coronary stents. Deﬁnite and probable
stent thrombosis were also reduced signiﬁcantly, by 25%
(47). As was the case for prasugrel, this beneﬁt was con-
sistent across all patient subgroups and types of stents.
Inﬂuence of smoking on antiplatelet inhibition. There
have previously been scattered reports on the effects of
smoking on the action of clopidogrel. In the PARADOXstudy, reported by Gurbel et al. (48), patients were
randomized to clopidogrel or prasugrel in a crossover design.
Inhibition of platelet activation on clopidogrel was lower in
nonsmokers than smokers. Inhibition of platelet activity was
greater with prasugrel than clopidogrel in both smokers and
nonsmokers and was not affected by smoking status in
patients receiving prasugrel. These results support the
so-called smoker’s paradox, in which the clinical beneﬁts
of clopidogrel are greater in smokers than in nonsmokers.
Oral anticoagulant agents. Two secondary analyses from
the ATLAS ACS 2–TIMI 51 trial (49) that evaluated the
oral factor Xa inhibitor rivaroxaban in addition to standard
therapy (including DAPT) in patients with ACS provided
greater insight into the potential role for oral anticoagulation
after ACS. Among the 7,817 patients with STEMI (>70%
of whom underwent PCI), the use of rivaroxaban starting on
average 4.7 days after the index event was associated with
a signiﬁcant 19% reduction in the composite of CV death,
MI, or stroke compared with placebo (49). The beneﬁt began
early and was statistically signiﬁcant at 30 days. Furthermore,
the very low-dose regimen of rivaroxaban (2.5 mg twice
daily) reduced CV death (2.5% vs. 4.2%, p ¼ 0.006)
compared with placebo. However, the addition of rivarox-
aban to DAPT signiﬁcantly increased major bleeding,
including intracranial hemorrhage, although rates of fatal
bleeding were low and not statistically different from placebo.
Among the 9,631 patients with ACS who received stents in
ATLAS ACS 2–TIMI 51 and were treated with DAPT, the
addition of rivaroxaban compared with placebo signiﬁcantly
reduced deﬁnite or probable stent thrombosis (as deﬁned by
the Academic Research Consortium) by 35% (95% conﬁ-
dence interval: 7% to 54%; p ¼ 0.017) (50). A mortality
reduction of 44% (95% conﬁdence interval: 11% to 65%) was
observed in patients who received the lower dose of rivar-
oxaban (2.5 mg twice daily) compared with placebo. These
ﬁndings helped shape the European Medicine Agency’s
approval of rivaroxaban after ACS in 2013; a similar review
by the U.S. Food and Drug Administration is ongoing.
Bleeding
One hundred sixteen years after aspirin was ﬁrst synthesized,
a consensus on the use of lower dose aspirin for patients with
ACS appears to have developed (6–8). A systematic review
of the literature including 136 studies with 289,330 patients
concluded that there was no improvement in clinical
outcomes with higher (>160 mg/day) maintenance doses of
aspirin compared with lower doses in patients with ACS
receiving coronary stents or being medically managed (51).
However, there was an excess of major bleeding of 23
per 1,000 with these higher doses of aspirin in medically
treated patients. An analysis from the HORIZONS-AMI
trial in patients with STEMI treated with primary PCI
concluded that higher dose aspirin (>200 mg/day) increased
major bleeding (adjusted HR: 2.80) and was not more
effective than low-dose aspirin in preventing recurrent
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209ischemic CV events (52). In addition, less severe forms of
bleeding, which are also more common with higher doses of
aspirin, have a negative impact on the quality of life and may
increase the need for re-hospitalization, as was shown in
the TRIUMPH study of 3,560 patients receiving DAPT
after MI (53).
Bleeding complications are particularly elevated in
patients requiring “triple therapy” with aspirin, a P2Y12
inhibitor, and a full dose of an oral anticoagulant agent (e.g.,
patients with ACS and atrial ﬁbrillation). An analysis of
nationwide registries in Denmark between 2000 and 2009
of 11,480 patients with atrial ﬁbrillation admitted with MI
or for PCI concluded that the excess risk for bleeding with
triple therapy begins early (within 90 days) and continues
through at least 1 year (54). These ﬁndings are important
because they suggest that there is no improvement in
tolerance over time with triple therapy, at least through
1 year of treatment. Although newer, more potent anti-
platelet therapies, such as prasugrel, have been shown to
reduce CV events (41), substitution of prasugrel for clopi-
dogrel in a small series of 377 patients with DES receiving
triple therapy resulted in a 3.2-fold increase in the hazard of
TIMI major or minor bleeding (55). Therefore, we believe
that patients who require triple therapy generally should
receive low-dose aspirin and clopidogrel for the minimal
duration recommended, warfarin with a target international
normalized ratio of 2.0 to 2.5, and, if coronary stenting is
indicated, a BMS.
A novel approach to avoiding triple therapy was tested
in the open-label WOEST trial (56), carried out in 573
patients with long-term indications for oral anticoagulation
undergoing coronary stenting. In the experimental arm,
aspirin was not administered, and the combination of clopi-
dogrel and an oral anticoagulant agent was compared with
triple therapy (aspirin 80 to 100 mg/day plus clopidogrel and
an oral anticoagulant agent). The risk for any bleeding was
substantially less with clopidogrel plus an oral anticoagulant
agent compared with triple therapy (19.4% vs. 44.4%,
p < 0.0001). Surprisingly, rates of the combined secondary
endpoint of death, MI, target vessel revascularization, stroke,
or stent thrombosis also were lower with dual compared
with triple therapy (HR: 0.60; 95% conﬁdence interval:
0.38 to 0.94). However, these data are not very robust given
the small number of events (81 events in the entire trial).
Additional large studies that limit the exposure of patients
to long-term triple antithrombotic regimens are needed.
Invasive Management
In this section, we highlight a few of the important publi-
cations on the invasive management of ACS and remind
readers that a dedicated review on interventional cardiology
was recently published in the Journal (57).
Current guidelines for the management of STEMI (6,7)
emphasize the importance of well-organized regional sys-
tems (58) to ensure rapid reperfusion therapy. For example,in North Carolina, an extension of regional coordination to
the entire state resulted in more rapid diagnosis of STEMI,
shorter transfer and door-to-device times, and an overall
increase in the use of reperfusion therapy (59). After a
statewide STEMI strategy to transport patients directly to
a PCI-capable hospital (bypassing nearer non-PCI hospitals)
was implemented, the mean time to reperfusion (by either
PCI or ﬁbrinolysis) was reduced by a mean of 31 min (60).
To reduce further the time to reperfusion therapy in
patients with STEMI, the emergency department was
bypassed by transferring appropriate patients from the
ambulance directly to the catheterization laboratory; this
strategy saved 20 to 30 min (61). It is likely that this
approach will be used with increasing frequency as patient
evaluation in ambulances becomes more precise.
Nevertheless, non-system-related delays that are difﬁcult
to anticipate (e.g., delays in providing consent, difﬁculty
with vascular access or crossing the culprit lesion, the need
for intubation) are not uncommon, occurring in 1 of 7
patients with STEMI in the National Cardiovascular
Data Registry, and are associated with a 6-fold increase in
mortality (62). When delays are expected and primary PCI
cannot be performed within 120 min of ﬁrst medical
contact, ﬁbrinolytic therapy is recommended (6–8). The
optimal method of reperfusion when the delays are shorter
(e.g., 60 to 120 min) is less clear.
Two complications, recurrent infarction and major
bleeding, are risk factors for subsequent mortality after
primary PCI in patients with STEMI. In an analysis of
2,002 patients, Kikkert et al. (63) found that this excess risk
persisted beyond 1 year in the case of recurrent MI.
However, in the case of bleeding, excess risk returned to
normal levels by 1 month. This observation is consistent
with results (for bleeding) observed in TRITON–TIMI 38.
Thus, although severe bleeding in patients with ACS
undergoing PCI certainly adds to early risk, if the bleeding
episode can be managed, it does not cause irreversible
damage, and the risk declines. However, recurrent infarction
causes irreversible damage to the myocardium and results in
persistent elevations of risk.
Although early primary PCI with intracoronary stent
implantation remains the gold standard for the treatment of
patients with STEMI, 2 new reports compared outcomes
in patients receiving BMS and DES. In an analysis of
28 randomized trials including 14,470 patients with STEMIs
who were followed for a total of 34,068 patient-
years, Bangalore et al. (64) reported that, compared with
BMS, sirolimus-eluting stents, paclitaxel-eluting stents, and
everolimus-eluting stents were associated with signiﬁcantly
reduced need for vessel revascularization, without increasing
the risk for stent thrombosis. Palmerini et al. (65) reported
that in an analysis of 12,453 patients with STEMI treated
with stents, the everolimus-eluting stent (a second-generation
DES) showed the most favorable safety and efﬁcacy proﬁle.
Similarly, in the EXAMINATION trial of 1,498 patients
with STEMI, everolimus-eluting stents and BMS had
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and any revascularization at 1 year; however, the rates of
repeat target lesion (2.1% vs. 5.0%, p ¼ 0.003) and vessel
(3.7% vs. 6.8%, p ¼ 0.008) revascularization were signiﬁ-
cantly lower in the everolimus-eluting stent group (66). In
the XAMI trial in 625 patients with STEMI randomized to
everolimus-eluting stents versus sirolimus-eluting stents
(ﬁrst-generation DES), the former signiﬁcantly reduced
major CV events (4.0% vs. 7.7%, p ¼ 0.048) compared
with sirolimus-eluting stents (67). Meanwhile in the
COMFORTABLE AMI trial, biolimus-eluting stents with
a biodegradable polymer reduced the primary endpoint of
major adverse cardiac events at 1 year compared with BMS
(4.3% vs. 8.7%, p ¼ 0.004) (68). In patients who are not
candidates for prolonged courses of DAPT (which is
necessary with DES to prevent late stent thrombosis),
BMS are preferred; however, most other patients would
appear to beneﬁt from newer generation DES.
Results with several adjunctive therapies during primary
PCI were reported in the past year. A retrospective analysis
of 2,567 consecutive patients with STEMI undergoing
primary PCI at a single center in the United Kingdom
showed that thrombus aspiration reduced both in-hospital
and longer term (mean 10 months) adjusted mortality
rates (69). However, the lack of randomization and the
absence of large-scale outcome trials comparing thrombec-
tomy with glycoprotein IIb/IIIa inhibition make it difﬁcult
to know which strategy is preferred. A meta-analysis of 18
trials including 3,936 patients comparing aspiration
thrombectomy with conventional primary PCI demon-
strated signiﬁcant reduction in major adverse cardiac events
(risk ratio: 0.76) and all-cause mortality (risk ratio: 0.71)
with aspiration thrombectomy (70). However, no differences
were found in major adverse cardiac events, mortality,
or other individual ischemic events between mechanical
thrombectomy and conventional primary PCI in a meta-
analysis of 7 trials including 1,598 patients (70). Last,
a randomized comparison of manual thrombus aspiration
with rheolytic thrombectomy (using high-velocity saline jets
in the distal catheter tip) showed that neither technique
completed removed the thrombus; no difference in residual
thrombus between the groups was observed using optical
coherence tomography (71). Both the ACCF and AHA
(6) and the European Society of Cardiology (7) STEMI
guidelines state that manual aspiration thrombectomy is
reasonable for patients undergoing primary PCI (Class IIa,
Level of Evidence: B).
Although early myocardial reperfusion is a cornerstone of
therapy for STEMI, reperfusion injury is a common adverse
effect, and therefore this treatment has been likened to
a 2-edged sword (72). Prevention of reperfusion injury in
AMI remains a major unmet need. New data suggest that
intracoronary microparticles (derived from platelets and
from endothelial cells) are correlated with ongoing throm-
bosis and microvascular dysfunction leading to microvascular
obstruction (73). Infusion of exenatide, a glucagon-likepeptide-1 analogue, beginning 15 min before primary PCI
signiﬁcantly increased myocardial salvage and reduced
infarct size as assessed by magnetic resonance imaging
compared with placebo in 172 patients with STEMI and
TIMI ﬂow grades of 0 or 1 (74). Intracoronary adenosine
was shown to improve ST-segment resolution and angio-
graphic microvascular obstruction in a placebo-controlled
3-arm trial of 240 patients with STEMI treated with PCI
and thrombus aspiration (75). In a randomized trial in
patients with STEMI undergoing primary PCI, both
intracoronary diltiazem and verapamil were more effective
than intracoronary nitroglycerin in preventing the no-reﬂow
phenomenon (a manifestation of reperfusion injury), as
assessed by the corrected TIMI frame count and by the
degree of ST-segment resolution after the intervention (76).
Ischemic post-conditioning (i.e., brief repeated periods of
ischemia induced by multiple low-pressure coronary artery
balloon inﬂations shortly after reperfusion) reduced infarct
size and myocardial edema compared with control in a pilot
trial of 50 patients with STEMI undergoing direct stent
implantation (77). In 544 patients with NSTEMI under-
going PCI randomized to 1 of 2 doses of the P-selectin
antagonist inclacumab versus placebo, the higher dose
(20 mg/kg) of inclacumab reduced myocardial damage
as assessed by release of cardiac biomarkers (78). The
EMBRACE-STEMI trial is comparing Bendavia (Stealth
Peptides, Newton Centre, Massachusetts), an intravenous
mitochondrial targeting peptide, with placebo in 300
patients with anterior STEMI undergoing primary PCI
to assess whether limiting reperfusion injury with this agent
can reduce infarct size (79). Larger studies are needed with
such interventions to determine whether these early beneﬁts
result in longer term improvement in left ventricular func-
tion and reductions in clinical events.
A meta-analysis of 6 randomized trials including 1,054
patients with cardiogenic shock after MI concluded that
intra-aortic balloon counterpulsation did not reduce mor-
tality, heart failure, or reinfarction (80). These ﬁndings were
subsequently conﬁrmed in the IABP-SHOCK II trial, a
randomized, prospective, open-label study of 606 patients
with cardiogenic shock complicating AMI, which showed
no difference in 30-day mortality or other secondary
endpoints (81). In the absence of more positive data in the
future, we anticipate that the next update of the STEMI
guidelines will downgrade the use of balloon counter-
pulsation from class IIa to IIb in such patients.
New data continue to support the use of radial arterial
access in patients with ACS. In an analysis of 294,769
patients with STEMI undergoing PCI in a U.S. database,
procedural success was similar, median door-to-balloon time
was only 4 min longer, and the adjusted odds of bleeding
were reduced signiﬁcantly by 38% with a radial compared
with a femoral approach (82).
In the United States, radial access accounted for 1 in 6
PCIs in 2012 (83) and is used more frequently in Western
Europe.
Table 5
Performance Measures in Patients With
Acute Coronary Syndromes
1. Aspirin administration at arrival
2. Aspirin prescription at discharge
3. Smoking cessation counseling
4. Beta-blocker prescription at discharge
5. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker if left
ventricular ejection fraction <40%
6. Statin prescription at discharge
7. Referral to cardiac rehabilitation
8. Assessment of left ventricular function
9. Door to balloon time <90 min (in patients undergoing primary PCI for STEMI)
Data from Krumholz et al. (93). Abbreviations as in Table 2.
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RIFLE-STEACS trial of 1,001 patients with STEMI
undergoing primary or rescue PCI. Patients randomized to
radial access had a signiﬁcantly lower rate of the primary
net adverse composite endpoint of cardiac death, stroke,
myocardial infarction, target lesion revascularization, and
bleeding (13.6% vs. 21.0%), with signiﬁcant reductions in
mortality, bleeding, and hospital stay (5 vs. 6 days) (84). A
similar signiﬁcant reduction in mortality was observed
with radial versus femoral artery access in the subgroup of
patients with STEMI in the RIVAL trial (1.3% vs. 3.2%),
whereas no similar reduction was observed among patients
with non–ST-segment elevation ACS in RIVAL (1.3% vs.
0.8%) (85). Although radial access was used in only 6.4%
of patients undergoing PCI for STEMI in the national
U.S. registry in 2011 (82), we expect this number to climb
rapidly as operators become more familiar with this
approach.
In a registry of 46,128 patients with STEMI undergoing
primary PCI in the United Kingdom, after adjustment for
baseline variables, radial access (compared with femoral
access) was associated with a signiﬁcantly lower mortality,
major bleeding, and site complications (86). In a registry of
patients undergoing PCI for ACS or chronic coronary artery
disease, hospital costs using radial access were, on average,
$830 lower than for femoral access, because of a slightly
reduced length of hospital stay (87).
Lipids
A recent observational registry in 24 U.S. hospitals showed
that 33% of patients had low-density lipoprotein cholesterol
levels higher than 100 mg/dl 6 months after AMI (i.e., they
did not meet the standard goal of <100 mg/dl), with fewer
than one-third achieving levels <70 mg/dl (the more
stringent optional goal) (88). Although no single factor is
responsible for the low rate of attainment of the goal level of
low-density lipoprotein cholesterol in high-risk patients,
underdosing (89) and interruption (90) of statin therapy are
2 frequent issues. In a propensity score–matched analysis in
a cohort of 17,080 patients >65 years of age with MIs
hospitalized in Ontario, Canada, high-intensity statin use
signiﬁcantly reduced the rate of repeat hospitalizations for
ACS without increasing the rate of new diabetes (89).
Quality of care. An analysis of 4 nationwide registries
spanning 1995 through 2010 described 4 trends that were
responsible for a temporal reduction in mortality in patients
with STEMI in France: 1) progressively more favorable
patient baseline characteristics over time, including declines
in age (from 66.2 to 63.3 years) and frequency of prior CV
events (from 26% to 17%); 2) a decrease in time from
symptom onset to ﬁrst medical contact (from 240 to 175
min), in part related to greater use of mobile intensive care
units; 3) an increase in the use of reperfusion therapy (from
49% to 75%), largely primary PCI; and 4) more frequent
use of guideline-recommended therapies (e.g., statins [from17% to 22%], angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers [from 19% to 28%]) before
presentation (91).
Although adherence to guideline-based therapies during
hospitalization for ACS continues to increase over time,
there is still room for improvement, particularly among
patients with NSTEMI, who are less likely than those
with STEMI to receive proven therapies at admission and at
discharge (92). One of the most successful tools to improve
guideline-based performance measures is the use of
computer-based physician order entry supplemented by
a decision support system. Use of such a computerized
system resulted in a higher rate of “perfect care,” deﬁned
as achievement of all 9 performance measures (Table 5)
recommended by the AHA and the American College of
Cardiology (93), compared with a standard paper order set
(89% vs. 61%, p < 0.001) in an analysis of 1,321 patients
with ACS admitted to a single CV center in New Orleans
(94). Referral to outpatient cardiac rehabilitation is the
recommendation that is least frequently adhered to among
the 9 performance measures, despite evidence that comple-
tion of cardiac rehabilitation is associated with adjusted
reductions in the risks for death of 41% and cardiac rehos-
pitalization of 32% (95). Another argument for rehabilita-
tion is that a slow gait speed is now recognized as a measure
of frailty, and among patients with STEMI, it was inde-
pendently associated with a 41% increase in the hazard of
a CV event (CV death, MI, or ischemic stroke) for each
decline of 0.1 m/s in gait speed (96). One approach that
appears to be promising to improve attendance at cardiac
rehabilitation is to schedule an orientation appointment
within 10 days of discharge, rather than the standard
approach (mean 35 days) (97). This simple, cost-neutral
intervention improved attendance to 77% (an absolute
increase of 18% over the standard), although larger studies
are needed to determine whether this will translate into
a clinical beneﬁt.
Additional strategies are also needed to improve long-term
adherence with treatment in the year after ACS. A rando-
mized controlled trial is comparing a 4-step intervention
(consisting of a pharmacist-led medication reconciliation and
tailoring, patient education, closer collaboration between
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system) with usual care to determine whether the inter-
vention can improve medication adherence and reduce
healthcare costs (98).
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